Frequency of myopathy in patients receiving lovastatin.
作者信息
Wortmann Robert L, Tipping Robert W, Levine Jeffrey G, Melin Jeffrey M
机构信息
University of Oklahoma Health Science Center, Tulsa, Oklahoma, USA.
出版信息
Am J Cardiol. 2005 Apr 15;95(8):983-5. doi: 10.1016/j.amjcard.2004.12.042.
Abstract
Lovastatin (Mevacor) 20 mg is being considered for nonprescription availability. Because the most severe untoward consequence of therapy with any statin is rhabdomyolysis, the clinical data for lovastatin pertaining to this adverse event were reviewed. Evidence to date, based on almost 2 decades of experience, points to an extremely low risk for myopathy and rhabdomyolysis associated with lovastatin.
摘要
Zotero 插件